Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis

被引:12
作者
Wallis, Robert S. [1 ,2 ,3 ]
Vinhas, Solange [4 ]
Janulionis, Ernestas [2 ]
机构
[1] Pfizer Specialty Care, New London, CT USA
[2] UMDNJ, New Jersey Med Sch, Newark, NJ USA
[3] CWRU Sch Med, Cleveland, OH USA
[4] Univ Fed Espirito Santo, Vitoria, Brazil
关键词
Tuberculosis; Whole blood culture; Immunity; Specificity; Diversity; MYCOBACTERIUM-BOVIS BCG; BACTERICIDAL ACTIVITY; ACTIVE TUBERCULOSIS; VACCINE DEVELOPMENT; INTERFERON-GAMMA; PROTECTION; RESPONSES; ATTENUATION; INFECTION; MARKERS;
D O I
10.1016/j.tube.2009.02.001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bactericidal assays have facilitated development of most modern vaccines, and have been proposed as indicators of protection after vaccination against tuberculosis. We examined control of intracellular growth of Mycobacterium tuberculosis in whole blood cultures of cured TB patients and tuberculin-negative healthy volunteers. Cured patients showed superior restriction of growth of the strain with which they had been infected. They similarly showed superior control of growth of a clinical strain (MP-28) that had become attenuated during passage. However, patients and healthy volunteers did not differ with regard to control of M. tuberculosis H37Ra. The ability of cured patients to control growth of the strain with which they had been infected correlated with MP-28, but not with H37Ra. These findings indicate M. tuberculosis MP-28 may be suitable to assess mycobacterial immunity as growth inhibition in whole blood culture, whereas H37Ra is not. However, additional studies will be required to confirm these observations in additional patient and microbial populations that are distinct according to geography and microbial and host genetics. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:221 / 224
页数:4
相关论文
共 26 条
[1]   Tuberculosis subunit vaccine development:: on the role of interferon-γ [J].
Agger, EM ;
Andersen, P .
VACCINE, 2001, 19 (17-19) :2298-2302
[2]   Comparative genomics of BCG vaccines by whole-genome DNA microarray [J].
Behr, MA ;
Wilson, MA ;
Gill, WP ;
Salamon, H ;
Schoolnik, GK ;
Rane, S ;
Small, PM .
SCIENCE, 1999, 284 (5419) :1520-1523
[3]  
CHENG SH, 1988, CLIN EXP IMMUNOL, V74, P20
[4]   Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis [J].
Cheon, SH ;
Kampmann, B ;
Hise, AG ;
Phillips, M ;
Song, HY ;
Landen, K ;
Li, Q ;
Larkin, R ;
Ellner, JJ ;
Silver, RF ;
Hoft, DF ;
Wallis, RS .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002, 9 (04) :901-907
[5]   Predictive value of a whole blood IFN-γ assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis [J].
Diel, Roland ;
Loddenkemper, Robert ;
Meywald-Walter, Karen ;
Niemann, Stefan ;
Nienhaus, Albert .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 177 (10) :1164-1170
[6]  
Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002
[7]  
EDWARDS LB, 1973, AM REV RESPIR DIS, V108, P1334
[8]   VARIATION IN PROTECTION BY BCG - IMPLICATIONS OF AND FOR HETEROLOGOUS IMMUNITY [J].
FINE, PEM .
LANCET, 1995, 346 (8986) :1339-1345
[9]   Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP [J].
Frigui, Wafa ;
Bottai, Daria ;
Majlessi, Laleh ;
Monot, Marc ;
Josselin, Emmanuelle ;
Brodin, Priscille ;
Garnier, Thierry ;
Gicquel, Brigitte ;
Martin, Carlos ;
Leclerc, Claude ;
Cole, Stewart T. ;
Brosch, Roland .
PLOS PATHOGENS, 2008, 4 (02)
[10]   Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development [J].
Gagneux, Sebastien ;
Small, Peter M. .
LANCET INFECTIOUS DISEASES, 2007, 7 (05) :328-337